Results 31 to 40 of about 4,151 (165)
Journal of Cosmetic Dermatology, Volume 25, Issue 6, June 2026.ABSTRACT Background Androgenetic alopecia (AGA) is the most prevalent type of hair loss, exerting a significant negative impact on patients' quality of life. The limited efficacy, potential adverse effects, and poor patient adherence of single‐agent therapies highlight substantial unmet needs in clinical management.
Zhuhao Lai, Yi Zhou, Rui Zhou
wiley +1 more source
Probing the Biological Plausibility of Fluoride as an Endocrine Disruptor
Birth Defects Research, Volume 118, Issue 5, May 2026.ABSTRACT Background Fluoride has come under recent scrutiny regarding concerns over potential neurodevelopmental and endocrine‐related toxicities, with recent reviews by the National Toxicology Program (NTP) and European Food Safety Authority (EFSA) concluding with moderate or reasonable confidence, respectively, that exposure to drinking water having ...
Ashley M. Mudd +2 more
wiley +1 more source
, 2021 Dutasteride is a competitive inhibitor of the enzyme 5-alpha-reductase and is commonly used to treat the symptoms of benign prostatic hyperplasia (BPH).
Romaniuk Maksym, Aksonov Pavlo
core +1 more source
The influence of age and the presence of prostate cancer on prostate volume, PSA and PSA density
BJU International, Volume 137, Issue 5, Page 805-812, May 2026.Objective To assess prostate volume (PV) changes with age in symptomatic and asymptomatic men with and without clinically significant prostate cancer (csPCa). In symptomatic patients, we additionally analysed the effect of age and csPCa on PSA and PSA‐density (PSA‐D) and compared these to current National Institute for Health and Care Excellence (NICE)
Jill Rusbridge +4 more
wiley +1 more source
Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia
, 2022 Background Androgenetic alopecia (AGA) is the most common cause of hair loss, often challenging to treat. While oral finasteride (1 mg/d) is an FDA-approved treatment for male AGA, oral minoxidil and oral dutasteride are not approved yet.
Greg Williams +2 more
core +1 more source
International Journal of Urology, Volume 33, Issue 5, May 2026.ABSTRACT Purpose There are few reports investigating urodynamic changes after radiotherapy and hormonal therapy (HT) for prostate cancer. We prospectively evaluated differences in bladder outlet obstruction (BOO) using pressure‐flow studies (PFS) before and after HT and radiotherapy in patients with high‐risk localized or locally advanced prostate ...
Yuki Kyoda +7 more
wiley +1 more source
Metastatic Prostate Cancer Masquerading as Locally Advanced Breast Cancer
Clinical Case Reports, Volume 14, Issue 4, April 2026.ABSTRACT We report a rare case of a 72‐year‐old man with prostatic adenocarcinoma metastasizing to gynecomastia breast tissue with ipsilateral axillary lymph node involvement. This presentation is notable for the absence of disseminated metastatic disease or prolonged androgen deprivation therapy.
Tess Howard +5 more
wiley +1 more source
, 2019 Dutasteride, a dual inhibitor of both type I and II 5α-reductases, is used to treat male pattern hair loss (MPHL). However, patient response to dutasteride varies in each individual, the cause of which is yet to be identified.
Soo Jung Kwak (7387775) +21 more
core +1 more source
, 2017 Dutasteride is a 5alpha-reductase inhibitor in clinical use to treat endocrine conditions. The present study investigated the neuroprotective mechanisms of action of dutasteride in intact and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned ...
Morissette M +4 more
core +1 more source
Journal of Cosmetic Dermatology, Volume 25, Issue 4, April 2026.ABSTRACT Background Hair loss is a common condition affecting both men and women, with significant psychosocial impact. While oral supplements are marketed to improve hair growth, their clinical efficacy remains debated. This systematic review aimed to evaluate the effectiveness and safety of commercial oral nutraceuticals for hair growth.
Razan Alanazi +8 more
wiley +1 more source